{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"20","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"description":"confirmed complete and partial responses per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.\".","dispersionType":"95% Confidence Interval","groups":[{"id":"OG000","title":"AZD2171 (Cediranib Maleate)"}],"paramType":"NUMBER","populationDescription":"Eligible patients who received any amount of AZD2171","reportingStatus":"POSTED","timeFrame":"Disease assessments for response were performed every 8 weeks for as long as the patient remained on protocol treatment, up to 5 years.","title":"Overall Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}